Results 81 to 90 of about 5,099,009 (221)

Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting

Haematologica, 2010
Background The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic Index in a population-based cohort and to study the relevance of its revisions.Design and Methods We analyzed data from 178 unselected patients with stage ...
Saskia A.M. van de Schans, Maryska L.G. Janssen-Heijnen, Marten R. Nijziel, Ewout W. Steyerberg, Dick Johan van Spronsen   +4 more
doaj   +1 more source

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non‐Hodgkin Lymphoma on Reproduction Patterns

European Journal of Haematology, EarlyView.
ABSTRACT Concerns about treatment‐related fertility impairment are common among young adult lymphoma survivors. Evidence on the impact of treatment for aggressive non‐Hodgkin lymphoma (NHL) on future childbearing is limited, although many individuals of reproductive age are affected.
Stefanie Antonilli, Anna Marklund, Joshua Entrop, Caroline E. Dietrich, Ingrid Glimelius, Tarec C. El‐Galaly, Alexander Fosså, Harald Holte, Karin E. Smedby, Knut B. Smeland, Sandra Eloranta   +10 more
wiley   +1 more source

MicroRNA profiling in B cell non-Hodgkin Lymphoma : focus on the role of MYC [PDF]

, 2013
Non-Hodgkinlymfoon is een kwaadaardige vorm van kanker die uitgaat van de lymfeklieren. De ziekte wordt gekenmerkt door specifieke chromosoomafwijkingen en door afwijkende patronen van genexpressie.
Robertus, Jan Lukas,, Robertus, Jan Lukas   +1 more
core   +1 more source

Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. [PDF]

, 2009
Contains fulltext : 80422.pdf (Publisher’s version ) (Open Access)Mantle cell lymphoma is a prime example of a well-defined entity based on morphology, phenotype, genetics and also clinical features.
Hebeda, Konnie, Kluin, P.M., Krieken, J.H.J.M. van, Schraders, M., Schuuring, Ed, Hebeda, K.M., Groenen, P.J.T.A., Oeschger, S., Schuuring, Ed; id_orcid, Schuuring, E., van Krieken, Johan H. J. M., Oeschger, Sabine, Schraders, Margit, Groenen, Patricia J. T. A., Kluin, Philip M., Hansmann, M.L., Hansmann, Martin-Leo   +16 more
core   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial

Haematologica, 2018
Mantle cell lymphoma patients have variable clinical courses, ranging from indolent cases that do not require immediate treatment to aggressive, rapidly progressing diseases.
Riccardo Bomben, Simone Ferrero, Tiziana D’Agaro, Michele Dal Bo, Alessandro Re, Andrea Evangelista, Angelo Michele Carella, Alberto Zamò, Umberto Vitolo, Paola Omedè, Chiara Rusconi, Luca Arcaini, Luigi Rigacci, Stefano Luminari, Andrea Piccin, Delong Liu, Adrian Wiestner, Gianluca Gaidano, Sergio Cortelazzo, Marco Ladetto, Valter Gattei   +20 more
doaj   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Emerging role of SOX11 in mantle cell lymphoma

, 2015
Venera Kuci,1,2,* Lena Nordström,1,2,* Mats Jerkeman,3 Sara Ek1,2 1Department of Immunotechnology, Lund University, Lund, Sweden; 2CREATE Health, Lund University, Lund, Sweden; 3Department of Oncology, Lund University, Lund, Sweden *These authors ...
Jerkeman M, Ek S, Kuci V, Nordström L
core  

Molecular diagnosis of malignant lymphoma : mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of malt [PDF]

, 2006
2006-01Malignant lymphoma is a heterogeneous category embracing three major types of lymphoid neoplasms: B cell neoplasms, T and NK cell neoplasms, and Hodgkin lymphoma.
Nakamura, Shigeo, 長坂, 徹郎, 榊原, 綾子, Kawai, Kumi, 下山, 芳江, Nagasaka, Tetsuro, 川井, 久美, Sakakibaya, Ayako, Shimoyama, Yoshie   +8 more
core   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source